clinical trial · NCT06013241
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
Chronic Rhinosinusitis Without Nasal PolypsBrensocatibPlaceboMometasone furoate nasal spray (MFNS)
brief summary
The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
started
Oct 30, 2023
primary completion
Sep 30, 2025
completion
Oct 30, 2025
last updated
Nov 10, 2025
official title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps - The BiRCh Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol